Search alternatives:
significantly reported » significantly related (Expand Search), significantly restored (Expand Search), significantly predicted (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
linear decrease » linear increase (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
significantly reported » significantly related (Expand Search), significantly restored (Expand Search), significantly predicted (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
linear decrease » linear increase (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
621
-
622
-
623
BT9 exhibits a dose- and time-dependent cytotoxic effect on medulloblastoma.
Published 2024Subjects: -
624
The percentage of studies that resulted in insect death increased over time.
Published 2025“…There was a significant decrease in the proportion of studies reporting just invasive handling (without death) over time (linear regression; t<sub>20,18</sub> = 4.00, p = 0.001, R<sup>2 </sup>= 0.44). …”
-
625
-
626
-
627
-
628
-
629
-
630
-
631
-
632
-
633
-
634
-
635
-
636
Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b>
Published 2025“…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”
-
637
-
638
-
639
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
-
640
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”